Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Coordinated attack

    Combo platter Strategy Coordinated attack Incyte Corp. (NASDAQ:INCY) is taking a pathway-based approach to building its pipeline by selecting targets that yield coordinated benefit if attacked simultaneously. The …

    Published on 3/24/2016
  • Figure: Mix and match

    Combo platter Strategy Mix and match Incyte Corp. (NASDAQ:INCY) is building a portfolio of anticancer compounds designed to have maximal synergies with each other. With the March announcement of its OX40-targeted …

    Published on 3/24/2016
  • Combo platter

    How Incyte aims to discover high synergy combo therapies

    Instead of playing catch-up to find cancer combos once molecules reach the clinic, Incyte is building combo-thinking into its preclinical strategy from the outset.

    Published on 3/24/2016
  • Transcending TransCelerate

    TransCelerate's preclinical move into toxicology

    TransCelerate has created the subsidiary BioCelerate to expand its reach into the preclinical space, starting with toxicology.

    Published on 3/17/2016
  • Table: Toxicology data initiatives

    Transcending TransCelerate Strategy Toxicology data initiatives Selected toxicology-centered consortia with large data-sharing components. Although several older groups are already well established, BioCelerate …

    Published on 3/17/2016
  • Box: Questioning UCP1

    Brown fat heats up Targets & Mechanisms Questioning UCP1 While there is evidence that manipulating targets such as FGF21, USF1 and SLIT2 promote both metabolic benefits and brown fat activity, it is still not clear…

    Published on 3/10/2016
  • Figure: Feel the burn

    Brown fat heats up Targets & Mechanisms Feel the burn Three studies have identified new molecular targets to treat obesity and metabolic diseases by enhancing thermogenesis - a process in which brown or beige …

    Published on 3/10/2016
  • Table: BioCentury Product Profile

    Brown fat heats up Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A small molecule inhibitor of the protease FAP C-terminal fragment of SLIT2 Concept A …

    Published on 3/10/2016
  • Table: Brown and beige fat targets

    Brown fat heats up Targets & Mechanisms Brown and beige fat targets Selected targets for modifying beige or brown fat to treat obesity and metabolic diseases, identified in the Distillery section of BioCentury …

    Published on 3/10/2016
  • Table: Brown and beige fat targets

    Brown fat heats up Targets & Mechanisms Brown and beige fat targets Selected targets for modifying beige or brown fat to treat obesity and metabolic diseases, identified in the Distillery section of BioCentury …

    Published on 3/10/2016
  • Brown fat heats up

    Casting a wide net for brown and beige fat targets in metabolic diseases

    The list of obesity targets in brown and beige fat is extending well beyond FGF21, with three studies showing new possibilities since the start of the year.

    Published on 3/10/2016
  • Figure: AKTing on SHANK3

    Rescue mission Targets & Mechanisms AKTing on SHANK3 A team at Novartis Institutes for BioMedical Research (NIBR) has identified three new autism targets (purple) and is designing small molecules against the …

    Published on 3/3/2016
  • Table: BioCentury Product Profile

    Rescue mission BioCentury Product Profile INNOVATION STAGE Product A small molecule inhibitor of CLK-2 or PPP2CA, or activator of AKT, that crosses the blood-brain barrier Concept A treatment for autism that …

    Published on 3/3/2016
  • Rescue mission

    Rescuing synapses in SHANK3 mice

    Two studies on the autism target SHANK3 suggest some symptoms can be reversed even after childhood and present a new small molecule strategy.

    Published on 3/3/2016
  • Figure: Four-armed reasoning

    Ironwood's brainy idea Product R&D Four-armed reasoning Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) wants to test its hypothesis that increased sGC signaling could mitigate Alzheimer's disease (AD) pathophysiology,…

    Published on 2/25/2016
  • Figure: NO hypertension

    Ironwood's brainy idea Product R&D NO hypertension Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) thinks the role of sGC in mediating NO-induced vasodilation can be exploited for more than just cardiovascular …

    Published on 2/25/2016
  • Table: BioCentury Product Profile

    Ironwood's brainy idea Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product A soluble guanylate cyclase (sGC) stimulator that concentrates in the brain Concept A treatment…

    Published on 2/25/2016
  • Ironwood's brainy idea

    Ironwood's path to the brain

    Ironwood's preclinical group is lining up AD and vascular dementia as the next indications to explore with the company's sGC platform.

    Published on 2/25/2016
  • Figure: One fox two fox

    Staking out foxholes: Figure: One fox two fox Staking out foxholes Targets & Mechanisms One fox, two fox Researchers from Memorial Sloan Kettering Cancer Center have shown the transcription factor FOXO1 keeps Tregs …

    Published on 2/18/2016
  • Figure: Surveillance state

    Staking out foxholes: Figure: Surveillance state Staking out foxholes Targets & Mechanisms Surveillance state Researchers from Memorial Sloan Kettering Cancer Center have identified a population of immune cells that…

    Published on 2/18/2016
  • Staking out foxholes

    Two MSKCC studies, two potential ways to improve antitumor immunity

    A pair of MSKCC studies unravels new biology for dialing down immune suppression and dialing up immunosurveillance.

    Published on 2/18/2016
  • Complementary ideas

    C4 levels drive schizophrenia risk

    A link between complement and schizophrenia raises new possibilities for treatment and a debate about pruning.

    Published on 2/11/2016
  • Figure: Structured risk

    Complementary ideas Targets & Mechanisms Structured risk A Harvard group has traced one of the strongest genetic risk factors for schizophrenia to the C4 gene. The team showed structural variation in C4 controls …

    Published on 2/11/2016
  • PPP tipping point

    BioCentury's annual look shows PPPs on the backslide

    BioCentury's annual roundup suggests the trend towards public-private partnerships may have peaked.

    Published on 2/4/2016
  • Figure: Continental Differences

    PPP tipping point Finance Continental Differences While U.S.-based companies and institutions continued to put faith in public-private partnerships (PPPs) in 2015 as a vehicle for advancing research, with almost as…

    Published on 2/4/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993